Selanc 5 mg/vial High Purity Polypeptides Selank CAS 121062-08-6 Safe Pass

   Selanc 5 mg/vial High Purity Polypeptides Selank CAS 121062-08-6 Safe Pass

Abstract

Selank is a synthetic derivative of the human body's naturally produced tetrapeptide Tuftsin. It is a hexapeptide whith a wide range of uses. It was first sinthesized in the late 1990's by the Institute of Molecular Genetics of the Russian Academy of Science. Selank is used as an anxiolytic in the therapy of anxiety and phobic disorders, including generalized anxiety. Its action is similar to that of mild benzodiazepins but without the sedative effects.

As a selective anxiolytic with a nootropic component, Selank can be used as treatment of depression, fear and general anxiety. It also reduces phsychic tension. This neuropeptide has passed all phases of clinical trials and is now being prepared for registration and mass production.

Specification

Clinical Trials

In clinical trials, the drug has shown to provide a sustained nootropic and anxioytic effect, which is useful for the treatment of generalized anxiety disorder (GAD). Selank has an advantage over traditional anxiety treatments, as it has no sedating or cognitive side effects and no associated addiction or withdrawal syndrome. Selank also has very low toxicity with an overdose proving harmless even up to 500 times the effective dose.

When released, the drug will be used as a 0.15% aqueous solution which is applied to the nasal mucosa in drops. It is thought that this is the best method for absorbing peptide based drugs. The drug can be used to suppress feelings of fear and anxiety in people with anxiety disorders and to stimulate learning and memory in healthy people.

Influence

The influence of a new heptapeptide Selank on microcirculation in anesthetized white rats was investigated. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a new synthetic anxiolytic which exerts obvious antiulcerogenic action and promotes healing of experimental ulcers.

Action of the peptide on gastric blood flow in the stomach by using the method ofhydrogenic clearance and Selank action on mesenteric lymphatic contractility by microscopical observation in situ, were studied. Selank fail to influence basal gastric blood flow but it can normalize blood flow reduced by indomethacin.

Dose

The study of dose-depended of Selank effect on lymphatic vessels contractility showed that its low concentration (10(-12)--10(-14) M) enhanced amplitude and increase frequency of lymphatic vessel contractions which indicates an enhancement of lymphatic flow. The high doses of peptide (10(-6)--10(-10) M) also augmented the contraction amplitude but decreased its frequency. The maintenance of adequate blood flow and lymphatic vessel contractility can be one of the mechanisms of the Selank antiulcerogenic properties.

Related Products